USPH

SEC source: 0001209191-17-067592 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,250

F1 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Brookner is a director of the Company on those dates.

SEC source: 0001209191-17-065206 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

F1 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Trier is a director of the Company on those dates.

SEC source: 0001209191-17-065362 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,187

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.25 - $72.75, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-065622 · doc4a.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.80 - $72.30, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Trier is a director of the Company on those dates.

SEC source: 0001209191-17-063065 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,500

F1 · shares: Shares donated to charitable organization

F2 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Brookner is a director of the Company on those dates.

SEC source: 0001209191-17-061687 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,750

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.60 - $68.85, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Kuntz is a director of the Company on those dates.

SEC source: 0001209191-17-061368 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,187

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.38- $69.15, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-059924 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,227

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.20- $66.95, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 40,442 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,816 shares on January 1, 2018; 4,941 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 2,441 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: $1,021 on each of April 1, July 1 and October 1, 2020; and $1,035 on January 1, 2021.

SEC source: 0001209191-17-059923 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,387

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.00- $66.58, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-059575 · doc4.xml · nonDerivative · entry 2

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,587

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.05 - $68.33, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-059575 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,987

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.15 - $70.35, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-055936 · doc4.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,422

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-055733 · doc4.xml · nonDerivative · entry 1

PULLINS JERALD L · CIK 0001242160 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,096

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-055734 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,750

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-055731 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-055730 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-056226 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,250

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-054809 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,500

F1 · shares: Shares donated to charitable organization.

SEC source: 0001209191-17-051055 · doc4.xml · nonDerivative · entry 2

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,236

F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-051055 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,830

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.00- $57.05, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-051587 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,235

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.00 - $59.02, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-049905 · doc4.xml · nonDerivative · entry 2

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,834

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.70- $59.80, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-049905 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,434

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00- $60.05, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-048682 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,387

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.00- $62.20, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-048528 · doc4.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,422

SEC source: 0001209191-17-023050 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,498

F1 · shares: The 8,175 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 510 shares each beginning on April 1, 2017 and thereafter with 510 on April 1, July 1, October 1 and January 1 of each year with the final 525 shares lapsing on January 1, 2021.

F2 · balance_after: Includes the 8,175 shares recently granted and 22,276 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-023051 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,227

F1 · shares: The 16,350 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 1,021 shares each beginning on April 1, 2017 and thereafter with 1,021 on April 1, July 1, October 1 and January 1 of each year with the final 1,035 shares lapsing on January 1, 2021.

F2 · balance_after: Includes the 16,350 shares recently granted and 44,540 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,816 on each of April 1, 2017, July 1, 2017, October 1, 2017 and January 1, 2018; 4,941 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 2,441 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: $1,021 on each of April 1, July 1 and October 1, 2020; and $1,035 on January 1, 2021.

SEC source: 0001209191-17-023049 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,387

F1 · shares: The 8,175 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 510 shares each beginning on April 1, 2017 and thereafter with 510 on April 1, July 1, October 1 and January 1 of each year with the final 525 shares lapsing on January 1, 2021.

F2 · balance_after: Includes the 8,175 shares recently granted and 22,276 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021.

SEC source: 0001209191-17-009871 · doc4.xml · nonDerivative · entry 2

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 2,881

F1 · shares: Shares donated to a charitable organization.

F2 · balance_after: Regg E. Swanson Revocable Trust is the Owner and Regg E. Swanson is Beneficiary and Trustee.

SEC source: 0001209191-17-009871 · doc4.xml · nonDerivative · entry 1

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 3,526

F1 · shares: Shares donated to a charitable organization.

F2 · balance_after: Regg E. Swanson Revocable Trust is the Owner and Regg E. Swanson is Beneficiary and Trustee.

SEC source: 0001209191-16-154666 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,750

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.30 - $68.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,250 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restricted lapse as to 625 shares on each of January 1, 2017 and April 1, 2017.

SEC source: 0001209191-16-151757 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,212

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.25 - $62.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 26,323 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.

SEC source: 0001209191-16-150412 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,323

F1 · balance_after: Includes 26,323 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.

SEC source: 0001209191-16-149560 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,212

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.00-$58.08, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 26,323 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.

SEC source: 0001209191-16-141956 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,212

F1 · balance_after: Includes 30,370 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on each of October 1, 2016, January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.

SEC source: 0001209191-16-142057 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,877

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.00 - $64.11, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 60,730 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 8095 shares on October 1, 2016, January 1, 2017; 5795 on each of April 1, 2017, July 1, 2017, October 1, 2017 and January 1, 2018; 3920 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 1420 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.